Compare DexCom, Inc. (DXCM) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? DexCom, Inc. trades at $90.8 (market cap $33.79B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.05. Which is the better fit depends on your goals.
| DXCM | VOOG | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $85.42 |
52-Week Low | $54.84 | $65.32 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
VOOG trades at $85.05, down 0.18% on the day but near 52-week highs, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent news highlights institutional accumulation and strong growth ETF comparisons, though RSI levels suggest potential overbought conditions. The fund focuses on large-cap growth stocks with low expense ratios, benefiting from tech sector leadership.
Outlook remains positive due to institutional inflows and growth exposure, but risks include tech concentration and market volatility. The fund's low costs and historical performance support long-term growth appeal, though investors should monitor valuation metrics amid elevated levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
